Premium
Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform
Author(s) -
TYAGI Pradeep,
CHUANG YaoChi,
YOSHIMURA Naoki,
KAUFMANN Jonathan,
CHANCELLOR Michael B.
Publication year - 2009
Publication title -
luts: lower urinary tract symptoms
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.451
H-Index - 15
eISSN - 1757-5672
pISSN - 1757-5664
DOI - 10.1111/j.1757-5672.2009.00040.x
Subject(s) - urothelium , liposome , irritation , pharmacology , cystometry , interstitial cystitis , protamine sulfate , medicine , protamine , drug delivery , urinary bladder , chemistry , urology , urinary system , immunology , heparin , biochemistry , organic chemistry
The clinical use of exogenous polysaccharides for the treatment of interstitial cystitis (IC) has lent credence to the concept of a dysfunctional urothelium as the cause of lower urinary tract symptoms (LUTS). Studies have shown that lipids in the apical membrane of the urothelium form an integral component of the permeability barrier in the bladder. This premise is supported by the therapeutic effect of empty liposomes in the irritated bladder. Instillation of liposomes comprised of natural phospholipids can augment bladder barrier function and support repair following injury from protamine sulfate and irritation with high potassium concentration. The mechanism of action proposed for the therapeutic effect of empty liposomes is that liposomes form a coat on the injured urothelium and block irritation of submucosal afferent nerves. Reduced afferent excitation after liposome instillation is reflected in prolonged intercontractile interval in cystometry. Liposomes offer a powerful new treatment option for IC using an intravesical route and as a platform for intravesical drug delivery.